Literature DB >> 20171325

Development of a patient adherence scale for exposure and response prevention therapy.

Helen Blair Simpson1, Michael Maher, Jessica R Page, Carly J Gibbons, Martin E Franklin, Edna B Foa.   

Abstract

Exposure and response prevention (EX/RP) is an evidence-based treatment for obsessive-compulsive disorder (OCD). For EX/RP to be maximally effective, it is believed that patients must adhere outside of sessions to the procedures they learn in therapy. To date, there is no standard measure of patient EX/RP adherence, despite the importance of accurately assessing EX/RP adherence in both clinical research and practice. This paper describes the development of the Patient EX/RP Adherence Scale (PEAS), which assesses the patient's between-session adherence to the therapist's EX/RP instructions, and presents initial data on the scale's reliability and validity. The scale was designed to focus on the key procedures of EX/RP and to be brief enough to be used at each treatment session. The scale demonstrates excellent interrater reliability and good face and content validity. The usefulness of the scale is considered in the context of being an important tool to researchers trying to understand and improve outcomes of EX/RP for OCD as well as to EX/RP therapists in clinical practice. Future research will need to test the scale's reliability and validity in a larger sample of patients over the course of treatment. 2009. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 20171325      PMCID: PMC3949512          DOI: 10.1016/j.beth.2008.12.002

Source DB:  PubMed          Journal:  Behav Ther        ISSN: 0005-7894


  9 in total

1.  The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS): an instrument for assessing obsessive-compulsive symptom dimensions.

Authors:  M C Rosario-Campos; E C Miguel; S Quatrano; P Chacon; Y Ferrao; D Findley; L Katsovich; L Scahill; R A King; S R Woody; D Tolin; E Hollander; Y Kano; J F Leckman
Journal:  Mol Psychiatry       Date:  2006-05       Impact factor: 15.992

2.  Early compliance and other factors predicting outcome of exposure for obsessive-compulsive disorder.

Authors:  L A De Araujo; L M Ito; I M Marks
Journal:  Br J Psychiatry       Date:  1996-12       Impact factor: 9.319

Review 3.  Cognitive behavioral therapy for obsessive-compulsive disorder: an update.

Authors:  Jonathan D Huppert; Martin E Franklin
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

4.  Differential effects of exposure and response prevention in obsessive-compulsive washers.

Authors:  E B Foa; G Steketee; J B Milby
Journal:  J Consult Clin Psychol       Date:  1980-02

5.  The effects of treatment compliance on outcome in cognitive-behavioral therapy for panic disorder: quality versus quantity.

Authors:  N B Schmidt; K Woolaway-Bickel
Journal:  J Consult Clin Psychol       Date:  2000-02

6.  Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder.

Authors:  Edna B Foa; Michael R Liebowitz; Michael J Kozak; Sharon Davies; Rafael Campeas; Martin E Franklin; Jonathan D Huppert; Kevin Kjernisted; Vivienne Rowan; Andrew B Schmidt; H Blair Simpson; Xin Tu
Journal:  Am J Psychiatry       Date:  2005-01       Impact factor: 18.112

7.  The Yale-Brown Obsessive Compulsive Scale. II. Validity.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; P Delgado; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

8.  Treatment compliance and outcome in obsessive-compulsive disorder.

Authors:  Jonathan S Abramowitz; Martin E Franklin; Lori A Zoellner; Corrie L DiBernardo
Journal:  Behav Modif       Date:  2002-09

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11
  9 in total
  16 in total

1.  Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Authors:  Helen Blair Simpson; Edna B Foa; Michael R Liebowitz; Jonathan D Huppert; Shawn Cahill; Michael J Maher; Carmen P McLean; James Bender; Sue M Marcus; Monnica T Williams; Jamie Weaver; Donna Vermes; Page E Van Meter; Carolyn I Rodriguez; Mark Powers; Anthony Pinto; Patricia Imms; Chang-Gyu Hahn; Raphael Campeas
Journal:  JAMA Psychiatry       Date:  2013-11       Impact factor: 21.596

2.  Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes well?

Authors:  Michael G Wheaton; Hanga Galfalvy; Shari A Steinman; Melanie M Wall; Edna B Foa; H Blair Simpson
Journal:  Behav Res Ther       Date:  2016-07-29

Review 3.  [Psychotherapy for obsessive-compulsive disorder: what is evidence based?].

Authors:  A K Külz; U Voderholzer
Journal:  Nervenarzt       Date:  2011-03       Impact factor: 1.214

4.  Patient adherence to cognitive-behavioral therapy predicts long-term outcome in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Sue M Marcus; Allan Zuckoff; Martin Franklin; Edna B Foa
Journal:  J Clin Psychiatry       Date:  2012-09       Impact factor: 4.384

5.  Patient adherence predicts outcome from cognitive behavioral therapy in obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Michael J Maher; Yuanjia Wang; Yuanyuan Bao; Edna B Foa; Martin Franklin
Journal:  J Consult Clin Psychol       Date:  2011-04

6.  Challenges using motivational interviewing as an adjunct to exposure therapy for obsessive-compulsive disorder.

Authors:  Helen Blair Simpson; Allan M Zuckoff; Michael J Maher; Jessica R Page; Martin E Franklin; Edna B Foa; Andrew B Schmidt; Yuanjia Wang
Journal:  Behav Res Ther       Date:  2010-06-01

7.  Innovations in the Delivery of Exposure and Response Prevention for Obsessive-Compulsive Disorder.

Authors:  Sapana R Patel; Jonathan Comer; Helen Blair Simpson
Journal:  Curr Top Behav Neurosci       Date:  2021

8.  Behavioral avoidance predicts treatment outcome with exposure and response prevention for obsessive-compulsive disorder.

Authors:  Michael G Wheaton; Marina Gershkovich; Thea Gallagher; Edna B Foa; H Blair Simpson
Journal:  Depress Anxiety       Date:  2018-02-02       Impact factor: 6.505

9.  Task-based fMRI predicts response and remission to exposure therapy in obsessive-compulsive disorder.

Authors:  David Pagliaccio; Rachel Middleton; Dianne Hezel; Shari Steinman; Ivar Snorrason; Marina Gershkovich; Raphael Campeas; Anthony Pinto; Page Van Meter; H Blair Simpson; Rachel Marsh
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-23       Impact factor: 11.205

Review 10.  Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.

Authors:  Joseph F McGuire; Adam B Lewin; Eric A Storch
Journal:  Expert Rev Neurother       Date:  2014-06-27       Impact factor: 4.618

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.